Application of bifidobacterium adolescentis B-201 in preparation of products for relieving asthenopia and protecting eyesight

Abstract

The invention provides application of bifidobacterium adolescentis B-201 in preparation of products for relieving asthenopia and protecting eyesight, and belongs to the field of microbial fermentation. The bifidobacterium adolescentis B-201 provided by the invention has the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.27234, and is preserved in the China General Microbiological Culture Collection Center (CGMCC) on April 27, 2023. The strain is subjected to culture fermentation and freeze drying to obtain bacterial powder, after auxiliary materials are added, the bacterial powder can be used for improving eye symptoms, increasing tear secretion amount, reducing ocular surface disease index scores and prolonging short-distance continuous eye using time, and the strain can be used for preparing products for relieving asthenopia and protecting eyesight.

Description

Technical Field

[0001] The invention belongs to the field of microbial fermentation, relates to Bifidobacterium adolescentis, and specifically relates to application of Bifidobacterium adolescentis B-201 in preparing products for relieving visual fatigue and protecting eyesight. Background Art

[0002] Probiotics were first proposed by German bacteriologist Werner Kollath in 1953, and translated as "beneficial to life". The International Scientific Association of Probiotics and Prebiotics revised the definition of probiotics in 2013 as: "Live microorganisms that, when administered in adequate amounts, can confer a beneficial effect on the health of the host". In addition, lactic acid bacteria and spore-forming bacteria, yeast and algae are classified as probiotics, with lactic acid bacteria being the most commonly used. At present, microecological preparations are mainly divided into three categories: probiotics, prebiotics and synbiotics. Microecological preparations can supplement the normal microorganisms lacking in the intestine in terms of quantity or type, adjust and maintain the balance of intestinal flora, stabilize the internal environment, enhance immunity, and promote the digestion and absorption of nutrients. Probiotics are used in probiotic microecological preparations, fermented foods, fermented dairy products, etc.

[0003] Since 1990, when Tissier first isolated bifidobacteria from the feces of breastfed infants, the beneficial function of bifidobacteria for human health has attracted much attention. Since then, scientists have isolated bifidobacteria from different ecological niches, such as the oral cavity, human vagina, and feces of various mammals. Bifidobacteria belong to the Bifidobacteriaceae family of the Actinomycetes phylum. They are Gram-positive bacteria, anaerobic, non-gas-producing, with an optimal growth temperature of 37°C and an optimal growth pH of 6.0-7.0. Bifidobacteria are often curved rods with various forms such as L, V, and Y, and the ends are often forked. The genus Bifidobacterium currently includes more than 90 species.

[0004] At present, the industrialization of bifidobacteria is mainly divided into the following five aspects: (1) Health care products market: Bifidobacterium health products are in the form of capsules, powders, liquids, etc. for consumers to take orally. These products usually have the effects of improving intestinal health, enhancing immunity, promoting digestive function, etc.; (2) Dairy products market: Bifidobacteria also have important applications in the dairy industry. Yogurt, fermented milk, cheese and other products often add bifidobacteria as active strains. Its addition can provide consumers with more choices while increasing the function and nutritional value of the products; (3) Dietary supplements: Dietary supplements may be bifidobacterium products or compound products containing multiple probiotic strains. These supplements can be selected by consumers according to their personal needs and health goals; (4) Medical field: In the medical field, bifidobacteria are used to prevent and treat intestinal-related diseases such as diarrhea, constipation, enteritis, colitis, etc., as well as some other diseases such as allergic rhinitis and skin diseases; (5) Animal feed: In addition to human applications, bifidobacteria are also widely used in the field of animal feed. Adding bifidobacteria to animal feed can improve the intestinal health of animals, promote nutrient absorption, and increase the efficiency of the farming industry.

[0005] Visual fatigue has become a common problem in modern life, especially in the context of digital learning, remote work and the popularity of smartphones. Studies have shown that 90% of digital device users have different degrees of visual fatigue symptoms. In my country, the incidence of visual fatigue is becoming more widespread and younger. The main manifestations are dry eyes, foreign body sensation, blurred vision, eye swelling, tearing, photophobia, heavy eyelids, etc. Mild visual fatigue is often difficult to attract people's attention, resulting in increasingly severe eye symptoms. Long-term and repeated visual fatigue may cause a variety of eye diseases, and severe cases may lead to cataracts. Visual fatigue is a syndrome in which organic lesions of the eye or the whole body are intertwined with mental (psychological) factors. It is a group of syndromes manifested as visual impairment, eye discomfort and systemic symptoms after using the eyes, so that normal visual work cannot be performed. In the current situation of human visual fatigue, the importance of preventing and relieving visual fatigue has become increasingly prominent. In recent years, researchers have brought the "intestinal-eye axis" to the public's vision. The relationship between intestinal microbiota and the eye has attracted more and more attention. It is well known that probiotics can effectively regulate intestinal flora and enhance immunity.

[0006] Prior art CN116445370A discloses a strain of Bifidobacterium breve JYBF-117 that can be made into a bacterial agent. Experiments have shown that the bacterial agent of Bifidobacterium breve JYBF-117 can effectively alleviate dry eye caused by environmental induction or vitamin A deficiency, increase tear secretion, improve tear film stability, inhibit the expression of dry eye-related inflammatory factors IL-1β, IL-6, and TNF-α, and reduce the degree of inflammation.

[0007] Prior art CN117643379A discloses the application of animal Bifidobacterium lactis subspecies i797 in eye protection products. The animal Bifidobacterium lactis subspecies i797 has the effect of relieving visual fatigue. In vitro simulation experiments have shown that it has good adhesion to intestinal epithelial cells and can be colonized in the body for a long time to exert its effect; zebrafish model experiments have shown that it can significantly prevent apoptosis of eye cells and can be used to prepare milk powder, yogurt and various probiotics with the effect of relieving visual fatigue.

[0008] With the development of the probiotics industry, there are also some potential hidden dangers and risks, such as improper use of the concept of probiotics, unclear core strains, and difficult to define functional properties. There has always been some controversy about the efficacy and safety of probiotics. Although the adverse reactions of probiotics seem to be mild, improper use may indeed cause potential health problems. my country started late in the development and utilization of probiotics, and most microbial research is mainly focused on the mutagenesis of fermentation strains and the increase in metabolite production, with less attention paid to the physiological functions of strains. Therefore, updating and developing new varieties, further improving the efficacy and safety of probiotic preparations, and standardizing the rational application of microecological preparations have become issues that need to be urgently addressed. Summary of the invention

[0009] The present invention aims to solve the problems in the prior art and provides the use of Bifidobacterium adolescentis B-201 in the preparation of products for relieving visual fatigue and protecting eyesight. Bifidobacterium adolescentis ) B-201, with the deposit number of CGMCC No.27234, was deposited in the General Microbiology Center of China Microbiological Culture Collection Administration on April 27, 2023. The strain is cultured, fermented, and freeze-dried to obtain bacterial powder. After adding auxiliary materials, it can be used to improve eye symptoms, increase tear secretion, reduce the ocular surface disease index score, and increase the time of continuous close-range eye use. The strain can be used to prepare products to relieve visual fatigue and protect vision.

[0010] To achieve the above purpose, the technical solution adopted by the present invention is as follows: The present invention provides Bifidobacterium adolescentis ( Bifidobacterium adolescentis ) The use of B-201 in the preparation of products for relieving visual fatigue and protecting eyesight. The preservation number of the Bifidobacterium adolescentis B-201 is CGMCC No.27234, and it was deposited in the General Microbiology Center of the China Microbiological Culture Collection Administration on April 27, 2023.

[0011] Preferably, the application includes at least one of the following: (1) Application in the preparation of products for preventing, alleviating and / or treating visual fatigue; (2) Use in the preparation of products for improving eye symptoms, wherein the eye symptoms include itchy eyes, eye pain, dry eyes, foreign body sensation, blurred vision, photophobia and tearing; (3) Application in the preparation of products for increasing tear secretion; (4) Use in the preparation of a product for reducing an ocular surface disease index score, wherein the ocular surface disease index score includes an evaluation of ocular symptoms, visual function, and environmental triggers; (5) Application in the preparation of products that increase the time of continuous close-range eye use.

[0012] Preferably, the product includes food, health care products or medicines.

[0013] Preferably, the medicine further comprises pharmaceutical excipients.

[0014] Preferably, the pharmaceutical excipients include at least one of fillers, binders, wetting agents, disintegrants, lubricants and flavoring agents commonly used in pharmacy.

[0015] Preferably, the drug is in the form of tablets, powders, capsules or granules.

[0016] Preferably, the food comprises dairy products, soy products or fruit and vegetable products.

[0017] Preferably, the dairy products include fermented milk, yogurt drinks, sour cream or cheese, the soy products include soy milk, fermented bean curd, fermented black beans or bean paste, and the fruit and vegetable products include cucumber, carrot, beet, celery or cabbage products. As a proven probiotic, it is easy to add Bifidobacterium adolescentis to various dairy products, soy products, fruit and vegetable products and other foods, which can not only add nutrients to the food, but also add flavor.

[0018] Preferably, the product further comprises a bacterial agent, wherein the bacterial agent comprises Bifidobacterium adolescentis B-201, or a culture, fermentation product or lyophilized powder containing Bifidobacterium adolescentis B-201.

[0019] Preferably, the bacterial agent comprises inactivated bacteria, fermentation broth, bacterial lysate, intracellular extract or metabolite after fermentation of Bifidobacterium adolescentis B-201.

[0020] Preferably, the bacterial agent is a solid preparation or a liquid preparation.

[0021] Preferably, the bacterial agent is a freeze-dried powder containing Bifidobacterium adolescentis B-201.

[0022] Preferably, the method for preparing the freeze-dried powder comprises the following steps: (1) inoculating Bifidobacterium adolescentis B-201 into a culture medium for activation; (2) inoculating the activated bacterial strain into a fermentation medium to obtain a seed solution; (3) inoculating the seed liquid into a fermentation medium for fermentation; (4) After fermentation, freeze-dry to obtain freeze-dried powder.

[0023] Preferably, the components of the fermentation medium include, by weight: 20-30 parts of sucrose, 10-15 parts of lactose, 10-20 parts of soy peptone, 3-8 parts of yeast powder, 10-15 parts of yeast peptone, 20-25 parts of Na2HPO3, 1-3 parts of citric acid, 0.1-1.0 parts of MgSO4·7H2O, 0.1-0.5 parts of MnSO4·5H2O, 0.5-1.5 parts of Tween-80 and 0.1-0.5 parts of L-cysteine ​​hydrochloride.

[0024] Preferably, the components of the fermentation medium include, by weight: 23.5 parts of sucrose, 12.0 parts of lactose, 15.0 parts of soy peptone, 5.0 parts of yeast powder, 12.0 parts of yeast peptone, 21.0 parts of Na2HPO3, 2 parts of citric acid, 0.6 parts of MgSO4·7H2O, 0.3 parts of MnSO4·5H2O, 1.0 parts of Tween-80 and 0.3 parts of L-cysteine ​​hydrochloride.

[0025] Compared with the prior art, the present invention has the following beneficial effects: The adolescent Bifidobacterium B-201 of the present invention is cultured, fermented and freeze-dried to obtain bacterial powder, which can be used to improve eye symptoms, increase tear secretion, reduce ocular surface disease index scores and increase close-range continuous eye use time after adding auxiliary materials. The strain can be used to prepare products that relieve visual fatigue and protect eyesight.

[0026] Collection Instructions Bacterial strain name: Bifidobacterium adolescentis B-201; Classification and naming: Bifidobacterium adolescentis Bifidobacterium adolescentis ; Depository: General Microbiology Center, China Microbiological Culture Collection Administration; Abbreviation of depository institution: CGMCC; Address: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing; Deposit date: April 27, 2023; The registration number of the Collection Center is: CGMCC No.27234. DETAILED DESCRIPTION

[0027] The following examples are provided to further understand the present invention better, are not limited to the best mode, and are not intended to limit the content and scope of the present invention. Any product identical or similar to the present invention obtained by anyone under the enlightenment of the present invention or by combining the features of the present invention with other prior arts, all falls within the protection scope of the present invention. If no specific experimental steps or conditions are indicated in the examples, the operation or conditions of the conventional experimental steps described in the literature in this area can be carried out. If the manufacturer is not indicated for the reagents or instruments used, they are all conventional reagent products that can be obtained commercially.

[0028] Example 1: Preparation of a bacterial powder Bacterial species: Bifidobacterium adolescentis B-201, with the deposit number of CGMCC No.27234; Preparation method of bacterial powder: 1) Activation of bacterial strains: The strain stored at -40°C was inoculated into a modified MRS liquid medium sterilized at 121°C for 15 minutes, cultured anaerobically at 37°C for 24 hours, and subcultured twice to obtain activated bacterial strains; 2) Optimize the preparation of culture medium: The optimized culture medium composition is as follows: sucrose 23.5kg, lactose 12.0kg, soy peptone 15.0kg, yeast powder 5.0kg, yeast peptone 12kg, Na2HPO321.0kg, citric acid 2.0kg, MgSO4·7H2O 0.6kg, MnSO4·5H2O 0.3kg, Tween-80 1.0kg, L-cysteine ​​hydrochloride 0.3kg, and distilled water 1000L.

[0029] The components of the optimized culture medium were prepared in proportion, mixed evenly, adjusted to pH 6.5, and sterilized at 121°C for 15 min.

[0030] 3) Preparation of seed solution: Take the activated bacteria and inoculate them into the optimized culture medium, and culture them anaerobically at 37°C until the pH value reaches 4.6. Then, the seed solution is obtained; 4) Inoculation and fermentation: The fermentation was carried out in a BLBIO-10GJ fermenter produced by Bailun Biotechnology. 100 L of optimized culture medium was placed in the fermenter. After sterilization, the seed liquid was inoculated into the optimized culture medium at a volume fraction of 1‰ and fermented for 18 h under controlled fermentation conditions. The fermentation conditions were controlled as follows: constant temperature culture at 30°C in the early stage of fermentation, and natural fermentation until the pH reached 5.0; then the fermentation temperature was adjusted to constant temperature culture at 37°C, and the pH was controlled to remain at 6.0 to maintain anaerobic fermentation.

[0031] During the fermentation process, the pH was controlled by adding a neutralizer, wherein the neutralizer was a 25% NaOH solution; and the anaerobic condition was achieved by passing nitrogen gas once every two hours.

[0032] 5) Termination of fermentation: When the bacteria stop producing acid, the fermentation is terminated to obtain a high-density fermentation liquid of each strain, and the number of live bacteria in the fermentation liquid reaches 2×10 10 cfu / ml or more. The cessation of acid production can be judged by the fact that the pH no longer decreases and the addition of the neutralizer stops.

[0033] 6) Freeze drying: a. Bacteria concentration: The high-density fermentation broth is centrifuged at 12000g to concentrate the bacteria; b. Add protective agent: Add 5 times the protective agent solution to the bacterial concentrate; the protective agent solution composition is as follows: 15kg skim milk, 12kg lactose, 1kg vitamin C, 1kg sodium glutamate, 1000L distilled water.

[0034] c. Drying: The bacterial suspension after adding the protective agent is freeze-dried (model: Sihuan LGJ-12C) to obtain freeze-dried bacterial powder, and the total number of viable bacteria in the bacterial powder reaches 1.0×10 11 CFU / g and above.

[0035] Example 2: Preparation of a bacterial agent Weigh 0.1 g of the bacterial powder in Example 1, add 0.9 g of maltodextrin as an auxiliary material, mix well, and the number of viable bacteria is not less than 1.0 × 10 10 CFU / g.

[0036] Comparative Example 1: Preparation of a bacterial powder Bacterial strain: Bifidobacterium animalis subsp. lactis BB-12, purchased from Chr. Hansen (Beijing) Trading Co., Ltd.

[0037] Except that the strain was changed to Bifidobacterium animalis subsp. lactis BB-12, the other parts were the same as those in Example 1.

[0038] Comparative Example 2: Preparation of a bacterial powder Bacterial strain: Bifidobacterium breve JYBF117 in CN116445370A was purchased from China General Microbiological Culture Collection Center with a collection number of CGMCC No.24536.

[0039] Except that the strain was changed to Bifidobacterium breve JYBF117, the other procedures were the same as those in Example 1.

[0040] Comparative Example 3: Preparation of a bacterial agent Weigh 0.1 g of the bacterial powder in Comparative Example 1, add 0.9 g of maltodextrin as an auxiliary material, mix well, and the number of viable bacteria is not less than 1.0 × 10 10 CFU / g.

[0041] Comparative Example 4: Preparation of a bacterial agent Weigh 0.1 g of the bacterial powder in Comparative Example 2, add 0.9 g of maltodextrin as an auxiliary material, mix well, and the number of viable bacteria is not less than 1.0 × 10 10 CFU / g.

[0042] Effect example: Probiotics help improve eye conditions (1) Preparation of inoculants According to Example 2, Comparative Example 3 and Comparative Example 4, bacterial preparations of Bifidobacterium adolescentis B-201, Bifidobacterium animalis subspecies lactis BB-12 and Bifidobacterium breve JYBF117 were prepared respectively.

[0043] (2) Experimental subjects A total of 120 subjects with visual fatigue were recruited from Inner Mongolia Agricultural University and divided into the following three groups according to the random number table method.

[0044] (3) Experimental groups Experimental group (30 people): taking the bacterial agent prepared in Example 2 (Bifidobacterium adolescentis B-201), 1×10 10 CFU / g; Comparative group A (30 people): taking the bacterial agent prepared in comparative example 3 (animal Bifidobacterium lactis subspecies BB-12 bacterial agent), 1×10 10 CFU / g; Comparative group B (30 people): taking the bacterial agent prepared in comparative example 4 (Bifidobacterium breve JYBF117 bacterial agent), 1×10 10 CFU / g; Placebo group (30 people): took the same dose of maltodextrin, whose packaging, powder form and content were the same as those of probiotics.

[0045] (4) Detection method Inclusion criteria: 1) Subjects ≥ 18 years old; 2) Symptoms such as itchy and dry eyes; 3) Subjects were informed and agreed.

[0046] Exclusion criteria: 1) suffering from other eye diseases; 2) mental disorders; 3) receiving related treatments two weeks before enrollment; 4) taking antibiotics two weeks before enrollment.

[0047] The subjects received probiotics or placebo intervention for 4 weeks. 1) Ocular symptom score: Before and 4 weeks after the intervention, the ocular symptoms (itchy eyes, dry eyes, eye pain, foreign body sensation, blurred vision, photophobia, and tearing) of the three groups of subjects were scored according to the severity of the four levels, no symptoms (0 points), mild symptoms (2 points), moderate symptoms (4 points), and severe symptoms (6 points). 2) Tear secretion test: Take a filter paper strip with a length of 3.5 cm and a width of 0.5 cm, and place it on the dome of 1 / 3 of the lower eyelid. Be careful not to touch the cornea. After closing both eyes lightly for 5 minutes, take it out and measure the infiltration length. 3) Scoring of the ocular surface disease index scale: Evaluate three aspects including ocular symptoms, visual function, and environmental triggers. The final score = (total score of answered questions × 25) / number of answered questions, with a total score of 100 points. The higher the score, the more severe the condition. Specifically including: All of the time in the past week - 4 points; most of the time - 3 points; half of the time - 2 points; occasionally - 1 point; never - 0 points; N / A - not applicable.

[0048] Do you have the following uncomfortable feelings? ① Eyes are afraid of light; ②It feels like sand has entered my eyes; ③ Eye pain or soreness; ④Things are blurry; ⑤Vision deteriorates.

[0049] Does eye discomfort affect the following activities? ⑥Reading; ⑦ Driving at night; ⑧Using a computer or mobile phone; ⑨Watch TV.

[0050] Do your eyes feel uncomfortable in the following environments? ⑩In windy / windy environment; ⑪In a relatively dry location or environment; ⑫In an air-conditioned place.

[0051] 4) Efficacy criteria: Disappearance of eye symptoms and continuous close-range eye use time of >45 min is considered markedly effective; alleviation of eye symptoms and continuous close-range eye use time of >30 min is considered effective; no change or aggravation of eye symptoms.

[0052] SPSS22.0 statistical data was used; P <0.05 was statistically significant.

[0053] (5) Experimental results 5.1 Comparison of ocular symptom scores Through the analysis of the subjects' eye symptoms, it was found that after the intervention of probiotics, it was found that probiotics can effectively improve the subjects' eye condition scores (including itchy eyes, eye pain, dry eyes, foreign body sensation, blurred vision, photophobia and tearing, see Table 1). The results showed that compared with the control group and the placebo group, the experimental group (B-201 bacterial agent) intervention can significantly alleviate the subjects' eye symptoms ( P <0.05), thereby relieving visual fatigue and protecting eyesight.

[0054] Table 1 Comparison of eye symptom scores before and after intervention

[0055] Note: The same letters in the same column indicate no significant difference (P>0.05), and different letters indicate significant difference (P<0.05).

[0056] 5.2 Tear secretion assessment Through the analysis of the tear secretion of the subjects, it was found that after the intervention of probiotics, it was found that probiotics can effectively increase the tear secretion of the subjects ( P <0.05), see Table 2. The results showed that compared with the control group and the placebo group, the experimental group (B-201 bacterial agent) intervention can significantly improve the tear secretion of the subjects, thereby relieving visual fatigue and protecting vision.

[0057] Table 2 Comparison of tear secretion of subjects before and after intervention

[0058] Note: The same letters in the same column indicate no significant difference (P>0.05), and different letters indicate significant difference (P<0.05).

[0059] 5.3 Comparison of Ocular Surface Disease Index Scores Through the analysis of the subjects' ocular surface disease index, it was found that after the intervention of probiotics, it was found that probiotics can effectively reduce the subjects' ocular surface disease index scores (including eye symptoms, visual function, and environmental triggers, see Table 3). The results showed that compared with the control group and the placebo group, the experimental group (B-201 bacterial agent) can significantly reduce the subjects' eye conditions ( P <0.05), thereby relieving visual fatigue and protecting eyesight.

[0060] Table 3 Comparison of OSDI of subjects before and after intervention

[0061] Note: The same letters in the same column indicate no significant difference (P>0.05), and different letters indicate significant difference (P<0.05).

[0062] 5.4 Comparison of eye symptoms and continuous close-range eye use time Through the analysis of the subjects' eye symptoms and the time of continuous close-range eye use, it was found that after the intervention of probiotics, it was found that probiotics can effectively improve the number of subjects' efficacy, as shown in Table 4. This shows that compared with the control group and the placebo group, the intervention of the experimental group (B-201 bacterial agent) can significantly improve the subjects' eye symptoms and increase the time of continuous close-range eye use ( P <0.05), thereby relieving visual fatigue and protecting eyesight.

[0063] Table 4 Comparison of the efficacy of eye symptoms and continuous close-range eye use time before and after intervention

[0064] Note: The numbers in parentheses represent the percentage of the total.

[0065] (6) Conclusion The bacterial agent prepared with the probiotic Bifidobacterium adolescentis B-201 can significantly improve eye symptoms (including itchy eyes, eye pain, dry eyes, foreign body sensation, blurred vision, photophobia and tearing), increase tear secretion, reduce the ocular surface disease index score (including eye symptoms, visual function, environmental triggers) and increase the time of continuous close-range eye use, thereby effectively relieving visual fatigue and playing a role in protecting vision.

[0066] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.

Claims

1. Bifidobacterium adolescentis ( Bifidobacterium adolescentis ) Application of B-201 in the preparation of products for relieving visual fatigue and protecting eyesight, characterized in that: The preservation number of the Bifidobacterium adolescentis B-201 is CGMCC No.27234, and it was deposited in the General Microbiology Center of China National Microbiological Culture Collection Administration on April 27, 2023.

2. The use according to claim 1, characterized in that: The application includes at least one of the following: (1) Application in the preparation of products for preventing, alleviating and / or treating visual fatigue; (2) Use in the preparation of products for improving eye symptoms, wherein the eye symptoms include itchy eyes, eye pain, dry eyes, foreign body sensation, blurred vision, photophobia and tearing; (3) Application in the preparation of products for increasing tear secretion; (4) Use in the preparation of a product for reducing an ocular surface disease index score, wherein the ocular surface disease index score includes an evaluation of ocular symptoms, visual function, and environmental triggers; (5) Application in the preparation of products that increase the time of continuous close-range eye use.

3. The use according to claim 1 or 2, characterized in that: The products include food, health products or medicines.

4. The use according to claim 3, characterized in that: The medicine also includes pharmaceutical excipients.

5. The use according to claim 4, characterized in that: The pharmaceutical excipients include at least one of fillers, binders, wetting agents, disintegrants, lubricants and flavoring agents commonly used in pharmacy.

6. The use according to claim 3, characterized in that: The medicine is in the form of tablets, powders, capsules or granules.

7. The use according to claim 3, characterized in that: The food includes dairy products, bean products or fruit and vegetable products.

8. The use according to claim 7, characterized in that: The dairy products include fermented milk, yogurt drinks, sour cream or cheese, the bean products include soy milk, fermented bean curd, fermented black beans or bean paste, and the fruit and vegetable products include cucumber, carrot, beet, celery or cabbage products.

9. The use according to claim 1 or 2, characterized in that: The product further comprises a bacterial agent, which comprises Bifidobacterium adolescentis B-201, or a culture, a fermentation product or a lyophilized powder containing Bifidobacterium adolescentis B-201.

10. The use according to claim 9, characterized in that: The bacterial agent includes inactivated bacteria, fermentation liquid, bacterial lysate, intracellular extract or metabolite after fermentation of Bifidobacterium adolescentis B-201.

11. The use according to claim 10, characterized in that: The bacterial agent is a solid preparation or a liquid preparation.

12. The use according to claim 11, characterized in that: The bacterial agent is freeze-dried powder containing Bifidobacterium adolescentis B-201.

13. The use according to claim 12, characterized in that: The preparation method of the freeze-dried powder comprises the following steps: (1) inoculating Bifidobacterium adolescentis B-201 into a culture medium for activation; (2) inoculating the activated bacterial strain into a fermentation medium to obtain a seed solution; (3) inoculating the seed liquid into a fermentation medium for fermentation; (4) After fermentation, freeze-dry to obtain freeze-dried powder.

14. The use according to claim 13, characterized in that The components of the fermentation medium include, by weight: 20-30 parts of sucrose, 10-15 parts of lactose, 10-20 parts of soy peptone, 3-8 parts of yeast powder, 10-15 parts of yeast peptone, 20-25 parts of Na2HPO3, 1-3 parts of citric acid, 0.1-1.0 parts of MgSO4·7H2O, 0.1-0.5 parts of MnSO4·5H2O, 0.5-1.5 parts of Tween-80 and 0.1-0.5 parts of L-cysteine ​​hydrochloride.

15. The use according to claim 14, characterized in that: The components of the fermentation medium include, by weight: 23.5 parts of sucrose, 12.0 parts of lactose, 15.0 parts of soy peptone, 5.0 parts of yeast powder, 12.0 parts of yeast peptone, 21.0 parts of Na2HPO3, 2 parts of citric acid, 0.6 parts of MgSO4·7H2O, 0.3 parts of MnSO4·5H2O, 1.0 parts of Tween-80 and 0.3 parts of L-cysteine ​​hydrochloride.

Images